Interleukin-17 in Inflammatory Myopathies |
| |
Authors: | Anne Tournadre Pierre Miossec |
| |
Institution: | 1.Department of Clinical Immunology and Rheumatology,H?pital Edouard Herriot,Lyon Cedex 03,France;2.Department of Rheumatology,CHU Clermont-Ferrand,Clermont-Ferrand,France |
| |
Abstract: | Since the identification of interleukin (IL)-17 as a T-cell–derived cytokine 15 years ago, the contribution of the T-helper
type 17 (Th17) pathway in inducing and maintaining chronic inflammation has been well-established, particularly in rheumatoid
arthritis. In addition to the main Th1 profile first suggested to contribute to inflammatory myopathies, the presence in inflamed muscle tissue of myositis of IL-17–producing cells, in association with activated dendritic cells,
suggests a local activation of the IL-23–Th17 pathway. IL-17 can act on muscle cells together with proinflammatory cytokines
produced by monocytes and innate immunity to amplify the immune response that could lead to muscle destruction. Evidence for
activation of the Th17 pathway in myositis lesions and in vitro effects of IL-17 on muscle cells suggest IL-17 as a therapeutic
target. Inhibitors of IL-17 have been tested in other inflammatory conditions, but the position of IL-17 inhibition in the
treatment of inflammatory myopathies remains to be defined. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|